

IVD For in Vitro Diagnostic Use



ARVI Screen Real-TM

Handbook

Multiplex RT-PCR detection and identification of human respiratory syncytial virus (hRSV); human metapneumovirus (hMpv); human parainfluenza virus-1-4 (hPiv); OC43, E229, NL63, and HKUI human coronavirus (hCov); human rhinovirus (hRv); human B, C, and E adenovirus (hAdv) and human bocavirus (hBov)

REF V57-100FRT

REF	TV57-100FRT
-----	-------------



NAME

ARVI Screen Real-TM

INTRODUCTION

Most acute respiratory diseases are viral infections. Acute respiratory viral infections (ARVI) are the most frequent illnesses experienced by most people globally. Young children have between five and seven of these illnesses per year, with a general decrease in frequency with increasing age. Adults will have about two such illnesses per year.

A wide variety of viruses, containing both RNA and DNA, cause acute respiratory infections. The most important viruses are rhinoviruses, coronaviruses, parainfluenza viruses, respiratory syncytial virus, adenoviruses, metapneumoviruses.

Rhinoviruses are the most frequent cause of the common cold. They circulate all year and are the major cause for the major autumn increase in respiratory illness. Multiple types of virus cause this rhinovirus outbreak, which is different from the typical outbreak of an infectious disease, in which only one viral type is responsible. Coronaviruses are also important agents of the common cold. Scientists have had difficulty in the laboratory working with these viruses, and the usual methods of virus detection have not yielded complete results. There are at least two major types of coronaviruses, each of which appears to occur over a limited period of time, usually in winter and spring.

There are four types of parainfluenza viruses. Parainfluenza type 4 is an agent that is sporadic in occurrence, producing little more than the common cold. As such, its activity is rarely described except when the virus is encountered as part of a comprehensive investigation in which a variety of different agents are sought. In contrast, whenever the severe respiratory illnesses causing hospitalization of young children are studied, parainfluenza types 1, 2, and 3, and RSV, are identified. Both types 1 and 2 most typically cause laryngotracheobronchitis, more commonly called croup. First infection with these viruses is essentially universal by three to four years of age, and, based on the number of infants and young children requiring medical attention, it can be estimated that well over 10 percent of children first encountering these viruses require medical attention specific for this syndrome. Like all respiratory viruses, these agents reinfect repeatedly throughout life, with later infections becoming milder or asymptomatic. Parainfluenza type 3 does not produce this syndrome, but rather one of pneumonia, often with features of obstruction. Again, first infection is universal at an early age, but only occasionally results in the most severe of the potential manifestations of the disease. Reinfection with or without symptoms also recurs throughout life.

INTENDED USE

ARVI Screen Real-TM PCR kit is an in vitro nucleic acid amplification test for multiplex detection and identification of specific nucleic acid fragments of pathogens that cause acute respiratory viral infections – human Respiratory Syncytial virus (hRSV) RNA; human Metapneumovirus (hMpv) RNA; human Parainfluenza virus-1-4 (hPiv) RNA; OC43, E229, NL63, and HKU 1 human Coronavirus (hCov) RNA; human Rhinovirus (hRv) RNA; human B, C, and E Adenovirus (hAdv) DNA; and human Bocavirus (hBov) DNA – in the clinical material (nasal and oropharyngeal swabs, sputum, aspirate of trachea, bronchoalveolar lavage, bronchial washing fluid, and autopsy material) by using Real-time PCR detection.

PRINCIPLE OF ASSAY

Kit **ARVI Screen Real-TM** is based on three major processes: isolation of RNA/DNA from specimens, reverse transcription of the RNA and multiplex Real Time amplification of 5 tubes for each sample. Each tube contains primers directed against regions of ARVI and Internal Control (IC) which serves as an amplification control for each individually processed specimen and to identify possible reaction inhibition.



MATERIALS PROVIDED

Module No.1: Real Time PCR kit (V57-100FRT)

Part N° 1 – "Reverta-L": Reverse transcription kit

- **RT-G-mix-1**, 20 x 0,01 ml;
- **RT-mix**, 20 x 0,125 ml;
- Reverse transcriptase (M-MLV), 2 x 0,06 ml;
- **TE-buffer**, 4 x 1,2 ml.

Contains reagents for 110 tests.

Part N° 2 - "ARVI Screen Real-TM": Real Time amplification kit

- **PCR-mix-1 hRSv hMpv,** 5 x 0,2 ml;
- **PCR-mix-1** *hPiv* **1/3**, 5 x 0,2 ml;
- PCR-mix-1 hPiv 2/4, 5 x 0,2 ml;
- **PCR-mix-1** *hCov*, 5 x 0,2 ml;
- **PCR-mix-1** *hAdv hBov,* 5 x 0,2 ml;
- PCR-mix-1 hRv, 5 x 0,2 ml;
- **PCR-mix-2-FRT,** 6 x 0,6 ml;
- TaqF Polymerase, 6 x 0,06 ml;
- Positive Control cDNA hRSv hMpv (C+hRSv-hMpv), 2 x 0,1 ml;
- Positive Control cDNA hPiv 1/3 (C+hPiv 1/3), 2 x 0,1 ml;
- Positive Control cDNA hPiv 2/4 (C+_{hPiv 2/4}), 2 x 0,1 ml;
- Positive Control cDNA hCov (C+hCov), 2 x 0,1 ml;
- Positive Control DNA hAdv hBov (C+hAdv-hBov), 2 x 0,1 ml;
- Positive Control cDNA hRv (C+_{hRv}), 2 x 0,1 ml;
- Internal Control DNA C+, 6 x 0,1 ml;
- **DNA-buffer,** 2 x 0,5 ml;
- Negative Control (C-), 2 x 1,2 ml;*
- Internal Control RNA C+ (IC RNA), 10 x 0,12 ml**

Contains reagents for 110 tests.

** add 10 µl of Internal Control RNA during the RNA purification procedure directly to the sample/lysis mixture

^{*} must be used in the isolation procedure as Negative Control of Extraction.

Module No.2: Complete Real Time PCR test with DNA/RNA purification kit (TV57-100FRT)

Part N° 1 – "Ribo-Sorb": RNA isolation kit

- Lysis Solution, 2 x 22,5 ml;
- Washing Solution, 2 x 20 ml;
- Sorbent, 2 x 1,25 ml.
- **RNA-eluent**, 10 x 0,5 ml;

Contains reagents for 100 tests.

Part N° 2 – "**Reverta-L**": Reverse transcription kit

- **RT-G-mix-1**, 20 x 0,01 ml;
- **RT-mix**, 20 x 0,125 ml;
- Reverse transcriptase (M-MLV), 4 x 0,03 ml;
- **TE-buffer**, 4 x 1,2 ml.

Contains reagents for 110 tests.

Part N° 3 - "ARVI Screen Real-TM": Real Time amplification kit

- **PCR-mix-1 hRSv hMpv,** 5 x 0,2 ml;
- PCR-mix-1 *hPiv* 1/3, 5 x 0,2 ml;
- PCR-mix-1 hPiv 2/4, 5 x 0,2 ml;
- **PCR-mix-1** *hCov*, 5 x 0,2 ml;
- **PCR-mix-1** *hAdv hBov*, 5 x 0,2 ml;
- PCR-mix-1 hRv, 5 x 0,2 ml;
- **PCR-mix-2-FRT,** 6 x 0,6 ml;
- TaqF Polymerase, 6 x 0,06 ml;
- Positive Control cDNA hRSv hMpv (C+hRSv-hMpv), 2 x 0,1 ml;
- Positive Control cDNA hPiv 1/3 (C+hPiv 1/3), 2 x 0,1 ml;
- Positive Control cDNA hPiv 2/4 (C+_{hPiv 2/4}), 2 x 0,1 ml;
- Positive Control cDNA hCov (C+_{hCov}), 2 x 0,1 ml;
- Positive Control DNA hAdv hBov (C+hAdv-hBov), 2 x 0,1 ml;
- Positive Control cDNA hRv (C+_{hRv}), 2 x 0,1 ml;
- Internal Control DNA C+, 6 x 0,1 ml;
- **DNA-buffer,** 2 x 0,5 ml;
- Negative Control (C-), 2 x 1,2 ml*;
- Internal Control RNA C+ (IC RNA), 10 x 0,12 ml**

Contains reagents for 110 tests.

^{*} must be used in the isolation procedure as Negative Control of Extraction.

^{**} add 10 μl of Internal Control RNA during the RNA purification procedure directly to the sample/lysis mixture

MATERIALS REQUIRED BUT NOT PROVIDED

Zone 1: sample preparation:

- RNA extraction kit (Module No. 1)
- Biological cabinet
- Desktop microcentrifuge for "eppendorf" type tubes
- 60°C ± 5°C dry heat block
- Vortex mixer
- Pipettors with aerosol barrier
- 1,5 ml polypropylene sterile tubes
- Disposable gloves, powderless
- Tube racks
- 70% Ethanol (freshly prepared mixture of reagent grade 96% ethanol and distilled water)
- Acetone
- Refrigerator
- Freezer

Zone 2: RT and amplification:

- Real Time Thermalcycler
- Workstation
- Pipettes (adjustable)
- Sterile tips with filters
- Tube racks

STORAGE INSTRUCTIONS

Ribo-Sorb must be stored at 2-8°C*.

Reverta-L and ARVI Screen Real-TM must be stored at -20°C.

The kits can be shipped at 2-8°C but should be stored -20°C immediately on receipt.

STABILITY

ARVI Screen Real-TM is stable up to the expiration date indicated on the kit label. The product will maintain performance through the control date printed on the label. Exposure to light, heat or humidity may affect the shelf life of some of the kit components and should be avoided. Repeated thawing and freezing of these reagents should be avoided, as this may reduce the sensitivity. Components stored under conditions other than those stated on the labels may not perform properly and may adversely affect the assay results.

QUALITY CONTROL

In accordance with Sacace's ISO 13485-Certified Quality Management System, each lot is tested against predetermined specifications to ensure consistent product quality.

WARNINGS AND PRECAUTIONS

IVD

In Vitro Diagnostic Medical Device

For *In Vitro* Diagnostic Use Only

The user should always pay attention to the following:

- Lysis Solution contains guanidine thiocyanate.* Guanidine thiocyanate is harmful if inhaled, or comes in contact with skin or if swallowed. Contact with acid releases toxic gas. (Xn; R: 20/21/22-36/37/38; S: 36/37/39).
- Store extracted positive material (samples, controls and amplicons) away from all other reagents and add it to the reaction mix in a separate area.
- Thaw all components thoroughly at room temperature before starting an assay.
- When thawed, mix the components and centrifuge briefly.
- Use disposable gloves, laboratory coats and eye protection when handling specimens and reagents. Thoroughly wash hands afterwards.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas.
- Do not use a kit after its expiration date.
- Dispose of all specimens and unused reagents in accordance with local authorities' regulations.
- Specimens should be considered potentially infectious and handled in a biological cabinet in accordance with appropriate biosafety practices.
- Clean and disinfect all sample or reagent spills using a disinfectant such as 0.5% sodium hypochlorite, or other suitable disinfectant.
- Avoid sample or reagent contact with the skin, eyes, and mucous membranes. If skin, eyes, or mucous membranes come into contact, rinse immediately with water and seek medical advice immediately.
- Material Safety Data Sheets (MSDS) are available on request.
- Use of this product should be limited to personnel trained in the techniques of DNA amplification.
- The laboratory process must be one-directional, it should begin in the Extraction Area and then move to the Amplification and Detection Areas. Do not return samples, equipment and reagents to the area in which the previous step was performed.



Some components of this kit contain sodium azide as a preservative. Do not use metal tubing for reagent transfer.

* Only for Module No.2

PRODUCT USE LIMITATIONS

All reagents may exclusively be used in in vitro diagnostics. Use of this product should be limited to personnel trained in the techniques of DNA amplification (UNI EN ISO 18113-2:2012). Strict compliance with the user manual is required for optimal PCR results. Attention should be paid to expiration dates printed on the box and labels of all components. Do not use a kit after its expiration date.

SAMPLE COLLECTION, STORAGE AND TRANSPORT

- Sputum, bronchial or tracheal lavage must be treated with the following procedure:
 - > Collect sputum into 50 mL single-use PP tubes with a screw cap.
 - In a biological safety cabinet, homogenize samples after mixing with equal volume of 4% NaOH solution. (*N-acetyl-L-cysteine may be added if required in the amount of 50-70 mg per sample)*. Mix intensely with a tube rotator for 5-20 minutes (depending on the density of a sample).
 - Centrifuge samples at 3000 rpm (2800-3000 g) for 15 min and carefully discard the supernatant leaving 500-1000 µl in the tube. Resuspend sediment and transfer it into a 1.5 ml tube.
 - Centrifuge samples at 12000 rpm for 5-10 min, discard the supernatant and use the same 1,5 ml sample tube for DNA isolation from sample sediment.
- tissue (~1,0 gr) homogenized with mechanical homogenizer or scalpel, glass sticks, teflon pestles and dissolved in 1,0 ml of saline water or PBS sterile (1 volume of tissue to 1 volumes of saline solution). Vortex vigorously and incubate 30 min at room temperature. Transfer the supernatant into a new 1,5 ml tube;
- nasopharyngeal swabs: swab area and place in "Eppendorf" tube with 0,5 ml of saline water or PBS sterile (Sacace Transport medium is recommended). Agitate vigorously. Repeat the swab and agitate in the same tube. Centrifuge at 1000g/min for 5 min. Discard the supernatant and leave about 100 µl of solution for RNA extraction.

Specimens can be stored at +2-8°C for no longer than 48 hours, or freeze at -20°C to -80°C.

Transportation of clinical specimens must comply with country, federal, state and local regulations for the transport of etiologic agents.

RNA ISOLATION

Any commercial RNA/DNA isolation kit, if IVD-CE validated for the specimen types indicated herein at the "SAMPLE COLLECTION, STORAGE AND TRANSPORT" paragraph, could be used.

Sacace Biotechnologies recommends to use the following kits:

- \Rightarrow **Ribo-Sorb-** (Sacace, REF K-2-1)
- ⇒ **DNA/RNA-Prep** (Sacace, REF K-2-9)

Please carry out RNA extraction according to the manufacture's instruction.

Add 10 µl of Internal Control (**RNA C+ (IC RNA)** during isolation procedure directly to the sample/lysis mixture.

SPECIMEN AND REAGENT PREPARATION*

- Lysis Solution and Washing Solution (in case of their storage at +2-8°C) should be warmed up to 60–65°C until disappearance of ice crystals. Prepare required quantity of 1.5 ml polypropylene tubes including one tube for Negative Control of Extraction.
- Add to each tube 450 μl Lysis Solution and 10 μl Internal Control RNC C+ (IC RNA). Mix by pipetting and incubate 5 min at room temperature.
- 3. Add **100 µI** of samples to the appropriate tube containing Lysis Solution and IC.
- 4. Prepare Controls as follows:
 - add 100 µl of C- Negative Control to the tube labeled Cneg
- 5. Vortex the tubes and centrifuge for 5 sec at 5000g. If the sample is not completely dissolved it is recommended to re-centrifuge the tube for 1 min at a maximum speed (12000-16000 g.) and transfer the supernatant into a new tube for RNA extraction
- 6. Vortex vigorously **Sorbent** and add **25 μl** to each tube.
- 7. Vortex for 5-7 sec and incubate all tubes for 10 min at room temperature. Vortex periodically.
- Centrifuge all tubes for 1 min at 10000g and using a micropipette with a plugged aerosol barrier tip, carefully remove and discard supernatant from each tube without disturbing the pellet. Change tips between tubes.
- 9. Add 400 µl of Washing Solution to each tube. Vortex vigorously, centrifuge for 1 min at 10000g. and using a micropipette with a plugged aerosol barrier tip, carefully remove and discard supernatant from each tube without disturbing the pellet. Change tips between tubes.
- 10. Add **500 μl** of **Ethanol al 70%** to each tube. Vortex vigorously, centrifuge for 1 min at 10000g. and using a micropipette with a plugged aerosol barrier tip, carefully remove and discard supernatant from each tube without disturbing the pellet. Change tips between tubes.
- 11. Repeat step 10.

- 12. Add **400 μl** of **Acetone** to each tube. Vortex vigorously, centrifuge for 1 min at 10000g and using a micropipette with a plugged aerosol barrier tip, carefully remove and discard supernatant from each tube without disturbing the pellet. Change tips between tubes.
- 13. Incubate all tubes with open cap for 10 min at 60°C.
- 14. Resuspend the pellet in **50 μl** of **RNA-eluent**. Incubate for 10 min at 60°C and vortex periodically. Centrifuge the tubes for 2 min at maximum speed (12000-16000 g).
- 15. The supernatant contains RNA ready for use. The RT-PCR can be performed the same day. If this is not possible, the RNA preparations can be stored at -80°C for up to one month.
- * Only for Module No.2

RT AND AMPLIFICATION

Reverse Transcription:

Prepare Reaction Mix: for 6 reactions, add 5,0 µl RT-G-mix-1 into the tube containing RT-mix and vortex for at least 5-10 seconds, centrifuge briefly. This mix is stable for 1 month at -20°C. Add 6 µl M-MLV into the tube with Reagent Mix, mix by pipetting, vortex for 3 sec, centrifuge for 5-7 sec (must be used immediately after the preparation).

(If it is necessary to test less than 6 samples add for each sample (N) in the new sterile tube **20*N μI** of **RT-G-mix-1 with RT-mix** and **1,0*N μI** of **M-MLV**).

- 2) Add **20 µl** of **Reaction Mix** into each sample tube.
- 3) Pipette 20 µl RNA samples to the appropriate tube. (If the Ribo-Sorb isolation kit is used as a RNA extraction kit, re-centrifuge all the tubes with extracted RNA for 2 min at maximum speed (12000-16000 g) and take carefully supernatant. N.B. don't disturb the pellet, sorbent inhibit reaction).Carefully mix by pipetting.
- 4) Place tubes into thermalcycler and incubate at 37°C for 30 minutes.
- 5) Dilute 1: 2 each obtained cDNA sample with TE-buffer (add 40 µl TE-buffer to each tube).

cDNA specimens could be stored at -20°C for a week or at -70°C during a year.

Amplification (reaction Mix 25 µl):

- 1. Prepare required quantity of tubes or PCR plate. Thaw the tubes with the reagents.
- For carrying out N reactions (including 4 controls: 3 PCR controls and 1 negative extraction control) mix in a new sterile tube: 10*N μl of PCR-mix-1, 5.0*N μl of PCR-mix-2-FRT and 0.5*N μl of TaqF polymerase.

Vortex the tube, then centrifuge shortly. Mark the tube with the name of the mix (for example hPiv 1/3). Repeat this procedure with each PCR-mix-1.

- Prepare for each sample 5 tubes (see image below) and add 15 μl of Reaction Mix into each tube.
- 4. Add **10 µl** of **cDNA** sample to appropriate tube with Reaction Mix.

- 5. Prepare for each mix 3 controls:
 - add 10 µl of DNA-buffer to the tube labeled PCR Negative Control;
 - add **10 µI** of **cDNA C+** to the tube labeled C_{pos};
 - add 10 µI of IC DNA to the tube labeled IC DNA_{Pos}



Create a temperature profile on your instrument as follows:

ARVI Screen Real-TM

	Rotor-type instruments ¹			Plate or modular type instruments ²		
Step	Temperature, °C	Time	Cycles	Temperature, °C	Time	Cycles
1	95	15 min	1	95	15 min	1
2	95	10 s	10	95	10 s	10
	54	20 s		54	25 s	
	72	10 s		72	25 s	
3	95	10 s	35	95	10 s	
	54	20 s Fluorescence detection*		54	25 s Fluorescence detection*	35
	72	10 s		72	25 s	Ī

¹ For example Rotor-Gene™ 3000/6000/Q (Corbett Research, Qiagen)

² For example, SaCycler-96[™] (Sacace), CFX/iQ5[™] (BioRad); Mx3005P[™] (Agilent), ABI® 7300/7500/StepOne Real Time PCR (Applied Biosystems), SmartCycler® (Cepheid), LineGeneK® (Bioer)

*Fluorescence is detected is in FAM/Green, JOE/Yellow/HEX/Cy3 and ROX/Orange/TexasRed fluorescent channels.



It is not allowed to perform *«Rhinovirus»* test together with other tests from ARVI Screen Real-TM PCR kit when working with **iCycler iQ** and **iQ5** instruments.

INSTRUMENT SETTINGS Rotor-type instruments

Channel	Calibrate/Gain Optimisation…	Threshold	More Settings/ Outlier Removal	Slope Correct
FAM/Green	from 5 FI to 10 FI	0.1	0 %	Off
JOE/Yellow	from 4 FI to 8 FI	0.1	5-10 %	Off
Rox/Orange	from 4 FI to 8 FI	0.1	5-10 %	Off

Plate- or modular type instruments

The threshold line should cross only sigmoid curves of signal accumulation of positive samples and should not cross the baseline; otherwise, the threshold level should be raised. Set the threshold at a level where fluorescence curves are linear and do not cross curves of the negative samples.

RESULTS INTERPRETATION

The results are interpreted by the software of real time pcr instrument by the crossing (or notcrossing) of the fluorescence curve with the threshold line.



Data analysis for each PCR-mix-1 should be performed individually, after withdrawal of tubes corresponding to the PCR-mix-1 used. For the *«Rhinovirus»* (hRv) test analysis, it is necessary to use **ONLY FAM** and **ROX** channels.

Table. Correspondence of PCR-mixes-1 and channels for ARVI pathogen detection

PCR-mix-1	Fluorescence detection			
	FAM/Green	JOE/Yellow/HEX/Cy3	ROX/Orange	
hRSv-hMpv	IC	hRSv	hMpv	
hAdv-hBov	IC	hBov	hAdv	
hRv	IC	-	hRv	
hPiv 1/3	IC	hPiv 3	hPiv 1	
hPiv 2/4	IC	hPiv 2	hPiv 4	
hCov	IC	NL-63, 229E	HKU-1, OC 43	

Principle of interpretation of results:

- DNA/RNA of an ARVI pathogen is **detected** if the Ct value for this sample is determined in the results grid in the corresponding channel. The fluorescence curve for this sample should cross the threshold line in the interval of exponential growth of the fluorescence curve.
- DNA/RNA of an ARVI pathogen is not detected if the Ct value for tested sample is not determined (absent) in the results grid in the corresponding channel and if the Ct value in the results grid in the FAM channel does not exceed the specified boundary value (Ct ≤ 32).
- Result is considered to be invalid if the Ct for the tested sample is not determined (absent) in the corresponding channel for ARVI pathogens and if the Ct value in the FAM/Green channel is absent or exceeds the specified boundary value (Ct > 32). In this case the analysis of the sample should be repeated from the DNA/RNA extraction step.

The results of analysis are considered reliable only if the results obtained for positive and negative controls of amplification and negative control of extraction are correct (see Table below).

		Ct value in channel		
Control	Stage for control	FAM/Green	JOE/Yellow/HEX/Cy3	ROX/Orange/TexasRed
		Detection of IC	Detection of ARVI pathogen	Detection of ARVI pathogen
NCE	RNA extraction	Pos (< 32)	Neg	Neg
NCA	Amplification	Neg	Neg	Neg
IC DNA C+	Amplification	Pos (< 28)	Neg	Neg
Pos C+	Amplification	Neg	Pos (< 26)*	Pos (< 26)

Table. Results for controls

* **Positive Control cDNA** hRv is not determined in the JOE channel.

PERFORMANCE CHARACTERISTICS

Analytical specificity

The specificity of this kit was confirmed by investigation of the following reference strains: *human Rhinoviruses* (13, 15, 16, 17, 21, 26, and 29 types). The specificity of the kit was also proved during examination of clinical material with subsequent confirmation by sequencing the amplification products of the following pathogens: *Parainfluenza virus-1-4; human Coronaviruses* OC43, E229, NL63, and HKUI; *human Adenoviruses* B, C, and E; and *human Bocavirus*. It is also possible to discriminate between closely related enteroviruses in the reaction for rhinovirus RNA detection. The adenovirus detection reaction is not intended for typing because of possible interaction with closely related adenoviruses of other types.

Non-specific reactions between the components of the PCR kit and cDNA/DNA of other viral (*Influenza A* and *B viruses*, Urbani SARS-associated *Coronavirus* (Frankfurt), *Coronaviruses* causing feline infectious peritonitis (F1, F2, and F5) and swine transmissible gastroenteritis (TGEV1, TGEV8, and TGEV9), *Herpes viruses*, *Cytomegalovirus*, *Enteroviruses* (Echo9 and Echo30), and 60 samples of cerebrospinal fluid from meningitis patients containing *Enterovirus* RNA) and bacterial (*Streptococcus* spp., *Staphylococcus aureus*, *Mycoplasma influenza*, *Chlamydophila pneumonia*, *Haemophilus influenza*, *Moraxella catarrhalis*, and *Legionella pneumophila*) agents that cause acute respiratory diseases as well as normal nasal and oropharyngeal human microflora and human cDNA/DNA were not observed.

Analytical sensitivity

The sensitivity of ARVI Screen Real-TM is not less than 1000 copies/ml.

TROUBLESHOOTING

- 1. Weak or absent signal of the IC (Fam (Green) channel): retesting of the sample is required.
 - The PCR was inhibited.
 - \Rightarrow Make sure that you use a recommended RNA extraction method and follow the manufacturer's instructions.
 - ⇒ Re-centrifuge all the tubes before pipetting the extracted RNA for 2 min at maximum speed (12000-16000 g) and take carefully supernatant. Don't disturb the pellet, sorbent inhibit reaction.
 - The reagents storage conditions didn't comply with the instructions.
 - \Rightarrow Check the storage conditions
 - The PCR conditions didn't comply with the instructions.
 - ⇒ Check the PCR conditions and for the IC detection select the fluorescence channel reported in the protocol.
 - The IC was not added to the sample during the pipetting of reagents.
 - \Rightarrow Make attention during the RNA extraction procedure.
- 2. Weak (Ct > 37) signal on the Joe (Yellow)/Cy3/HEX or Rox/Orange/TexasRed channel: retesting of the sample is required.
- 3. No signal with the positive controls of amplification.
 - Incorrect programming of the temperature profile of the used instrument;
 - Configuration of the PCR reaction was not right.
 - The reagents storage conditions didn't comply with the instructions
 - The reagent kit is expired.
 - \Rightarrow Check programming of the used instrument, storage conditions, the expiration date of the reagents and then repeat PCR.
- 4. Joe (Yellow)/Cy3/HEX or Rox/Orange/TexasRed signal with Negative Control of extraction.
 - Contamination during RNA extraction procedure. All samples results are invalid.
 - ⇒ Decontaminate all surfaces and instruments with sodium hypochlorite and ethanol.
 - \Rightarrow Use only filter tips during the extraction procedure. Change tips among tubes.
 - \Rightarrow Repeat the RNA extraction with the new set of reagents.
- 5. Any signal with Negative PCR Control.
 - Contamination during PCR preparation procedure. All samples results are invalid.
 - ⇒ Decontaminate all surfaces and instruments with sodium hypochlorite and ethanol or special DNA decontamination reagents.
 - \Rightarrow Pipette the Positive controls at the end.
 - \Rightarrow Repeat the PCR preparation with the new set of reagents.

KEY TO SYMBOLS USED

REF	List Number	\bigwedge	Caution!
LOT	Lot Number	\sum	Contains sufficient for <n> tests</n>
IVD	For <i>in Vitro</i> Diagnostic Use	VER	Version
	Store at	NCA	Negative Control of Amplification
	Manufacturer	NCE	Negative control of Extraction
i	Consult instructions for use	C+	Positive Control of Amplification
\sum	Expiration Date	IC	Internal Control

- * SaCycler™ is a registered trademark of Sacace Biotechnologies
 * CFX™ and iQ5™ are registered trademarks of Bio-Rad Laboratories
 * Rotor-Gene™ is a registered trademark of Qiagen
 * MX3005P® is a registered trademark of Agilent Technologies
 * ABI® is a registered trademark of Applied Biosystems
 * LineGeneK® is a registered trademark of Bioer
 * SmartCycler® is a registered trademark of Cepheid



Sacace Biotechnologies Srl via Scalabrini, 44 – 22100 – Como – Italy Tel +390314892927 Fax +390314892926 mail: info@sacace.com web: www.sacace.com